These findings suggest that CD64 and CD169 could become practical biomarkers to guide early diagnosis, treatment decisions, and patient triage in pediatric emergency settings, ultimately improving care for children with respiratory infections. This evidence concerns the gene SIGLEC1 and respiratory tract infectious disorder.